Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Lewy body dementia

Topic: Brain proteins, microglia and lab models

Plain-language summary

In the central Lewy body diseases (LBDs) Parkinson's disease and dementia with Lewy bodies (DLB), by the time parkinsonism or cognitive dysfunction manifests, substantial central neurodegeneration has already occurred. Biomarkers of preclinical disease are needed to test strategies that might delay the onset of symptomatic central LBDs and extend healthspan. The prospective, longitudinal PDRisk study asked whether cardiac sympathetic neuroimaging, cerebrospinal fluid catecholamine metabolites, cardiovascular physiological biomarkers, and alpha-synuclein seeding activity predict central LBDs in at-risk individuals. This review highlights and builds on several findings from this unique study. Some concepts induced from the present and previous data are: 1) Central LBDs can begin outside the brain ("body-first"), with early involvement of cardiac sympathetic nerves as evidenced by ¹⁸F-dopamine positron emission tomography (PET) and normal initial putamen dopaminergic innervation by ¹⁸F-DOPA PET. 2) DLB can follow a similar body-first progression pattern. 3) Body-first LBDs entail tri-phasic temporal sequences, corresponding conceptually to homeostasis, dyshomeostasis, and symptomatic disease, noted in the heart years before the striatum. 4) LBDs feature a vesicular storage defect in extant catecholaminergic terminals, exemplifying the "sick-but-not-dead" phenomenon. 5) There are multiple other functional abnormalities in residual catecholaminergic terminals in LBDs. 6) Based on computational modeling, disease-modifying treatments begun in the dyshomeostatic phase might delay the onset of symptomatic LBDs, compressing morbidity.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study. This review of the longitudinal PDRisk study describes candidate biomarkers, such as cardiac sympathetic neuroimaging and cerebrospinal fluid measures, that might detect Lewy body diseases before symptoms appear. The stated goal is to enable testing of strategies that might delay symptom onset, but no such strategy is tested here.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Goldstein, D. S. (2026). Preclinical Catecholaminergic Biomarkers of Central Lewy Body Diseases. Journal of Clinical Neurology. https://doi.org/10.3988/jcn.2025.0629

Vancouver

Goldstein DS. Preclinical Catecholaminergic Biomarkers of Central Lewy Body Diseases. Journal of Clinical Neurology. 2026. doi:10.3988/jcn.2025.0629. PMID: 41517809.

BibTeX

@article{goldstein2026-41517809,
  author  = {Goldstein, David S.},
  title   = {{Preclinical Catecholaminergic Biomarkers of Central Lewy Body Diseases}},
  journal = {Journal of Clinical Neurology},
  year    = {2026},
  doi     = {10.3988/jcn.2025.0629},
  pmid    = {41517809},
  url     = {https://doi.org/10.3988/jcn.2025.0629}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review of the longitudinal PDRisk study describes candidate biomarkers, such as cardiac sympathetic neuroimaging and cerebrospinal fluid measures, that might detect Lewy body diseases before symptoms appear. The stated goal is to enable testing of strategies that might delay symptom onset, but no such strategy is tested here.

Study details

How this study scored 49/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 4 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 4 of 4; Institution's track record left out, no data; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 48 of the 97 points it could be judged on, which is 49 of 100. Total 49 of 100.48 of the 97 points we could judge = 49 of 100

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 48 of the 97 points we could judge it on, which is 49 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Clinical Neurology)
Journal's citation record 1 / 4 Journal of Clinical Neurology: journal h-index 75 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 3 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.5 citations a year over 2 year(s) since 2026
Impact for its field and year 4 / 6 Cited 13.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author David S. Goldstein: h-index 110 (OpenAlex, whole career)
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41517809)
Free to read 2 / 2 Free to read
Points 48 / 97 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 48 of the 97 points we could judge it on is 49 out of 100.
Total 49 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Lewy body dementia from nearby years

Also tagged “lewy”

1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Lewy body dementia

See all studies in Lewy body dementia →